ClinicalTrials.gg
TerminatedNCT05275673Updated Apr 24, 2025Results posted

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of sapanisertib in Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer and Squamous Non-Small Cell Neoplasm of Lung, sponsored by Faeth Therapeutics. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Faeth Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision - funding issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
2,683rd of 2,995
7 · median 56
Started
2022
with 168 others
Phase 2
1,078 of 3,368
119 open now
Registered
2,651st of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 2,683rd largest by enrollment of the 2,995 interventional ones that give a count, is one of 169 that started in 2022, is one of 1,078 in phase 2, and was the 2,651st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior systemic therapies for metastatic disease including platinum-doublet chemotherapy and a programmed cell death 1 ligand 1 (PD-L1) inhibitor. The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sqNSCLC as two separate groups: Group A: NFE2L2-mutated sqNSCLC and Group B: NFE2L2-WT sqNSCLC.

Read the detailed description

NFE2L2 mutation status for all patients will be identified using local or central next generation sequencing (NGS) testing on archival or fresh tissue or circulating tumor deoxyribonucleic acid (ctDNA), the results of which must be reviewed and approved by the Sponsor prior to enrollment. Each group will be randomized 1:1 to one of two doses/schedules of sapanisertib. Approximately 30 NFE2L2-mutant and 20 NFE2L2-wild type patients will be enrolled. Patients will be treated with sapanisertib until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, withdrawal of consent, or death.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Squamous Non-small-cell Lung Cancer
  • Squamous Non-Small Cell Neoplasm of Lung
  • NFE2L2 Gene Mutation

Keywords

  • NSCLC
  • sqNSCLC
  • NFE2L2
  • Next Generation Sequencing
  • NGS
  • Mutation
  • Relapsed
  • Refractory
  • Squamous
  • NRF2
  • Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage IV squamous NSCLC.
  • Disease progression during or after prior systemic therapy for disease, which must include platinum-doublet chemotherapy and therapy (anti-PD-(L)1 +/-anti-CTLA-4), if approved and available, administered as separate or in combination.
  • Has study-eligible mutation in NFE2L2 or wild-type NFE2L2 using NGS from a College of American Pathologists- (CAP)-accredited and/or a Clinical Laboratory Improvement Amendments- (CLIA)-certified laboratory
  • Must have at least one radiographically per v1.1 defined as a lesion that is ≥ 10 mm in longest diameter or lymph node that is ≥ 15 mm in short axis imaged by computerized tomography (CT) scan or Magnetic Resonance Imaging (MRI).
  • Target lesions situated in a previously irradiated area may be considered measurable if progression has been demonstrated subsequent to radiation therapy.
  • (ECOG) Performance Status of 0-1
  • Adequate Organ Function Laboratory Findings: (ANC): ≥1,500/mm3, : ≥9.0 g/dL * Transfusions and growth factors must not be used within 2 weeks prior to randomization to meet these requirements, : ≥ 100,000/mm3, Calculated (CrCl): ≥ 40mL/min, Serum total : ≤ 1.5× (ULN) OR ≤ 3 mg/dL for patients with Gilbert's disease, (SGOT) and ALT (SGPT): ≤ 2.5× ULN OR ≤ 5× ULN for patients with liver metastases, Fasting triglycerides: \< 300 mg/dL, Fasting serum glucose: \<160 mg/dL
  • A female patient of must:

    1. Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study treatment
    2. Agree to use acceptable methods of (See Section 8.1.2) during the study and for a minimum of 14 days following the last dose of sapanisertib
    3. females (no menses for >1 year without an alternative medical cause) and surgically sterilized females are exempt from these requirements.
  • Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential and refrain from donating sperm during the study and for a minimum of 14 days following the last dose of sapanisertib.

Exclusion criteria

Exclusion Criteria:

  • Non-squamous cell histology and mixed histology tumors with any small-cell/neuroendocrine component.
  • Prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment per investigator's discretion.
  • Receipt before the first dose of study drug of any of the following:

    i. Any agent within 4 weeks. ii. Chemotherapy with 3 weeks (6 weeks for nitrosoureas or mitomycin C) iii. Any radiotherapy within 2 weeks prior to randomization with the exception of palliative radiotherapy for isolated tumor lesions

  • Major surgery or other anticancer therapy not previously specified within 4 weeks.
  • Unable or unwilling to discontinue proton pump inhibitor (PPI) use ≥ 5 days prior to randomization.
  • Interstitial lung disease or a history of pneumonitis that required oral or intravenous treatment.
  • Any condition including social, psychiatric or medical (including uncontrolled significant concurrent illness) that in the opinion of the Investigator could interfere with treatment or protocol-related procedures.
  • Patients who are pregnant or lactating.
  • Symptomatic ascites or pleural effusion. Exception: Patients who are clinically stable following treatment for these conditions (including therapeutic thoraco-or paracentesis) are eligible.
  • nausea and vomiting, uncontrolled diarrhea, malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes or other situation that may preclude adequate absorption of oral study medication.
  • Infection requiring more than 5 days of parenteral antibiotics, antivirals, or antifungals within two weeks prior to randomization.
  • Patients receiving systemic corticosteroids greater than prednisone 10 mg or equivalent (excluding inhalers or low-dose hormone replacement therapy) within the 7 days before treatment initiation.
  • Previous intolerance to mammalian target of rapamycin (mTOR), AKT, or dual PI3K/mTOR inhibitors.
  • Patients with symptomatic, active/untreated central nervous system and/or are not eligible.
  • Significant active cardiovascular disease
  • Participants who are known to be -positive, unless assessed to be healthy with a low risk of AIDS-related outcomes.
  • Known active or C infection.
  • Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of the study drug.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Group A - NFE2L2 Mutation, Dosing Cohort 1

    sapanisertib 3 mg once daily (QD)

    Drug: sapanisertib

  • Experimental
    Group A - NFE2L2 Mutation, Dosing Cohort 2

    sapanisertib 2 mg twice daily (BID)

    Drug: sapanisertib

  • Experimental
    Group B - NFE2L2 Wild-Type, Dosing Cohort 1

    sapanisertib 3 mg QD

    Drug: sapanisertib

  • Experimental
    Group B - NFE2L2 Wild-Type, Dosing Cohort 2

    sapanisertib 2 mg BID

    Drug: sapanisertib

Interventions

  • capsules for oral administration

    Also known as: CB-228

06

What researchers measure

Primary outcomes

  1. Investigator-Assessed Overall Response Rate (ORR) Per RECIST v1.1.

    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the RECIST v1.1 criteria as assessed by the investigator.

    Time frame: 36 months

  2. Number of Participants With Adverse Events (AEs), Serious AEs, and Deaths

    An adverse event (AE) is defined as any untoward, undesired, or unplanned medical occurrence in a patient administered a medicinal product whether or not considered drug related. A serious adverse event (SAE) is defined as an AE that occurs after receiving study treatment (or after signing informed consent and before receiving study treatment if due to a protocol-mandated procedure) that either results in death, is life-threatening, requires inpatient hospitalization, results in persistent or significant disability, results in congenital anomaly or birth defect, or otherwise meets criteria as an important medical event. Events were categorized as related or not related to study drug, and event severity was graded as mild (1), moderate (2), severe (3), life-threatening (4), or fatal (5).

    Time frame: From the first dose through 28 days after the last dose of sapanisertib (up to a maximum of 124 days).

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is the time between the first documentation of partial response (PR) or a complete response (CR) to the first documentation of progressive disease or death, whichever occurs first.

    Time frame: 36 months

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: 36 months

  3. Overall Survival (OS) at 6 and 12 Months

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Months 6 and 12

07

Results

Posted Apr 24, 2025

Participant flow

This trial was discontinued on 24 Jan 2023 due to limitations in resources. Of approximately 64 participants planned for the study, 7 participants (11%) were enrolled.

Participant flow — Overall Study
MilestoneSapanisertib 3 mg QDSapanisertib 2 mg BID
Started43
Completed00
Not completed43
Withdrew: Study termination by sponsor23
Withdrew: Death10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryInvestigator-Assessed Overall Response Rate (ORR) Per RECIST v1.1.

ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the RECIST v1.1 criteria as assessed by the investigator.

Time frame:
36 months

No measurements were reported for this outcome.

PrimaryNumber of Participants With Adverse Events (AEs), Serious AEs, and Deaths

An adverse event (AE) is defined as any untoward, undesired, or unplanned medical occurrence in a patient administered a medicinal product whether or not considered drug related. A serious adverse event (SAE) is defined as an AE that occurs after receiving study treatment (or after signing informed consent and before receiving study treatment if due to a protocol-mandated procedure) that either results in death, is life-threatening, requires inpatient hospitalization, results in persistent or significant disability, results in congenital anomaly or birth defect, or otherwise meets criteria as an important medical event. Events were categorized as related or not related to study drug, and event severity was graded as mild (1), moderate (2), severe (3), life-threatening (4), or fatal (5).

Time frame:
From the first dose through 28 days after the last dose of sapanisertib (up to a maximum of 124 days).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious AEs, and Deaths
ParticipantsSapanisertib 3 mg QDSapanisertib 2 mg BID
AE32
AE >= Grade 311
Serious AE11
AE Related to Study Drug31
Death10
SecondaryDuration of Response (DOR)

DOR is the time between the first documentation of partial response (PR) or a complete response (CR) to the first documentation of progressive disease or death, whichever occurs first.

Time frame:
36 months

No measurements were reported for this outcome.

SecondaryProgression-Free Survival (PFS)

PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first.

Time frame:
36 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) at 6 and 12 Months

OS is defined as the time from randomization to death due to any cause.

Time frame:
Months 6 and 12

No measurements were reported for this outcome.

Adverse events

Collected over From enrollment (all-cause mortality) or from the first dose of study drug (adverse events) through the last day on study (up to a maximum of 124 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sapanisertib 3 mg QD1/4 (25%)1/4 (25%)3/4 (75%)
Sapanisertib 2 mg BID0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventSapanisertib 3 mg QDSapanisertib 2 mg BID
SepsisInfections and infestations0/41/3
Cardiac arrestCardiac disorders1/40/3
Most frequent other events
Showing 10 of 13
Most frequent other events
EventSapanisertib 3 mg QDSapanisertib 2 mg BID
PruritusSkin and subcutaneous tissue disorders1/41/3
COVID-19Infections and infestations0/41/3
Blood creatinine increasedInvestigations0/41/3
NauseaGastrointestinal disorders0/41/3
Rash pustularInfections and infestations0/41/3
DiarrhoeaGastrointestinal disorders1/40/3
EpistaxisRespiratory, thoracic and mediastinal disorders1/40/3
Dental cariesGastrointestinal disorders1/40/3
ToothacheGastrointestinal disorders1/40/3
Urinary tract infectionInfections and infestations1/40/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sapanisertib 3 mg QDSapanisertib 2 mg BIDTotal
<=18 years000
Between 18 and 65 years213
>=65 years224
Sex: Female, Male
Sex: Female, Male(Participants)Sapanisertib 3 mg QDSapanisertib 2 mg BIDTotal
Female325
Male112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sapanisertib 3 mg QDSapanisertib 2 mg BIDTotal
Hispanic or Latino000
Not Hispanic or Latino437
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sapanisertib 3 mg QDSapanisertib 2 mg BIDTotal
White336
Black101
Unknown000
NFE2L2 Status
NFE2L2 Status(Participants)Sapanisertib 3 mg QDSapanisertib 2 mg BIDTotal
Participants with NFE2L2-mutated sqNSCLC213
Participants with NFE2L2-wild type (WT) sqNSCLC224
08

Study locations

14 sites
  • UC Davis Comprehensive Cancer Center
    Davis, California 95817, United States
  • Providence Medical Group Santa Rosa - Cancer Center
    Santa Rosa, California 95403, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Florida Cancer Specialists
    Tallahassee, Florida 32308, United States
  • Norton Cancer Institute, Downtown
    Louisville, Kentucky 40202, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University - Patient Care Coordinator Center
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center - Thoracic
    New York, New York 10065, United States
  • Zangmeister Cancer Center
    Columbus, Ohio 43219, United States
  • Providence Cancer Institute Franz Clinic
    Portland, Oregon 97213, United States
  • UPMC Cancer Pavilion
    Pittsburgh, Pennsylvania 15232, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Virginia Cancer Specialist, PC
    Fairfax, Virginia 22031, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We do not plan to share the individual participant data with other researchers

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Jan 2023, 6 months.

Results were first posted in Apr 2025, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Mar 11, 2022
StartActual
Jul 21, 2022
Primary completionActual
Jan 24, 2023
CompletionActual
Jan 24, 2023
Results first posted
Apr 24, 2025
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05275673
Lead sponsor
Faeth Therapeutics
Responsible party
Sponsor
First posted
Mar 11, 2022
Start date
Jul 21, 2022
Primary completion
Jan 24, 2023
Completion
Jan 24, 2023
Results posted
Apr 24, 2025
Last update
Apr 24, 2025

Study contacts

Paul Paik
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sapanisertib

Start the discussion